AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6345373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 40 mg
Number of subjects: 12
Study 6345373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (both doses)
Number of subjects: 12
Study 6345373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30889802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile diabetes management system (MDMS)
Number of subjects: 44
Study 30889802 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 44
Study 29338073 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of androgen deprivation therapy (ADT)
Number of subjects: 206
Study 29338073 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 206
Study 26606872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory approach combined with traditional swallowing therapy
Number of subjects: 82
Study 26606872 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor approach combined with traditional swallowing therapy
Number of subjects: 82
Study 26606872 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 82
Study 25979762 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative methylation-specific PCR (Q-MSP)
Number of subjects: 0
Study 25979762 — intervention group
Group type: EXPERIMENTAL
Intervention: MethyLight
Number of subjects: 0
Study 25979762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisulfite pyrosequencing
Number of subjects: 0
Study 22595020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (400 mg daily for 12 weeks)
Number of subjects: 49
Study 22595020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 18838493 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 33
Study 18838493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17503044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia released prior to wound closure (Group A)
Number of subjects: 43
Study 17503044 — intervention group
Group type: COMPARATOR
Intervention: Ischaemia released after suturing and bandaging (Group B)
Number of subjects: 43
Study 15759065 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interpersonal counseling (TIP-C)
Number of subjects: 48
Study 15759065 — intervention group
Group type: COMPARATOR
Intervention: Usual care attentional control
Number of subjects: 48
Study 11948052 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary revascularization
Number of subjects: 22
Study 11948052 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary revascularization
Number of subjects: 22
Study 10496112 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCD)
Number of subjects: 7
Study 7793589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine hydrochloride (4-6 micrograms/kg/min) with colloid
Number of subjects: 12
Study 7793589 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 12
Study 1920698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 99
Study 1920698 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and flexibility training
Number of subjects: 99
Study 1920698 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 99
Study 6355318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin treatment
Number of subjects: 575
Study 6355318 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 575
Study 31840813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target below 120 mm Hg)
Number of subjects: 1167
Study 31840813 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP target below 140 mm Hg)
Number of subjects: 1167
Study 31350650 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use device
Number of subjects: 40
Study 31350650 — intervention group
Group type: COMPARATOR
Intervention: Reusable device
Number of subjects: 40
Study 28490554 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based clinician-focussed clinical rule and printed leaflet with individualised child health information
Number of subjects: 501
Study 28490554 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 501
Study 25727445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign-Supported English (SSE)
Number of subjects: 104
Study 25727445 — intervention group
Group type: COMPARATOR
Intervention: English-only input (Control)
Number of subjects: 104
Study 25008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS treatment (2 mA, 35 cm2, two times daily stimulation for 13 min with a 20‐min interval for five consecutive days)
Number of subjects: 33
Study 25008145 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33
Study 25008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS treatment
Number of subjects: 33
Study 22835219 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (25 mg three times daily for 3 months)
Number of subjects: 24
Study 22835219 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 19444613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intake of 15 g of dietary fiber rich in phenolic antioxidants
Number of subjects: 10
Study 19444613 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 4)
Number of subjects: 10
Study 17561952 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a starting dose of 12.5 mg/day, target dose of 50 mg/day for patients <30 kg and 75 mg/day for patients >30 kg over 4 weeks
Number of subjects: 88
Study 17561952 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) at a starting dose of 10 mg/kg/day, target dose of 20 mg/kg/day over 4 weeks
Number of subjects: 88
Study 17561952 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at minimum target dose
Number of subjects: 88
Study 17382742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily
Number of subjects: 2802
Study 17382742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2802
Study 14751204 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 527
Study 10836730 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan, 80 mg, o.d. (AT1 antagonist)
Number of subjects: 20
Study 10836730 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (placebo)
Number of subjects: 20
Study 9108809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus divalproex sodium
Number of subjects: 12
Study 9108809 — intervention group
Group type: COMPARATOR
Intervention: Lithium alone (placebo group)
Number of subjects: 12
Study 9108809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 8476409 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Phobia and Anxiety Inventory (SPAI)
Number of subjects: 0
Study 3957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 24
Study 3957880 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 24
Study 30626650 — intervention group
Group type: EXPERIMENTAL
Intervention: l-serine (400 mg/kg/day)
Number of subjects: 18
Study 30626650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28435240 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-containing treatments (budesonide/formoterol or budesonide)
Number of subjects: 10570
Study 28435240 — intervention group
Group type: COMPARATOR
Intervention: Non-budesonide-containing treatments (formoterol or placebo)
Number of subjects: 10570
Study 28435240 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 10570
Study 28435240 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 10570
Study 24909399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system
Number of subjects: 136
Study 24909399 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP)
Number of subjects: 136
Study 24909399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume >70 mL
Number of subjects: 136
Study 24909399 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP) in patients with prostate volume >70 mL
Number of subjects: 136
Study 24909399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume ≤ 70 mL
Number of subjects: 136
Study 23800443 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages delivered twice daily for three months (n=24)
Number of subjects: 54
Study 23800443 — intervention group
Group type: COMPARATOR
Intervention: Fortnightly thank you text message (n=24)
Number of subjects: 54
Study 20689965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/day)
Number of subjects: 39
Study 22253969 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dairy (HD; three dairy servings, diet totaling 1,400 mg/day)
Number of subjects: 106
Study 22253969 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dairy (HD)
Number of subjects: 106
Study 22253969 — intervention group
Group type: COMPARATOR
Intervention: High Calcium (HC; 1,400 mg/day)
Number of subjects: 106
Study 22253969 — intervention group
Group type: COMPARATOR
Intervention: Low Calcium (LC; 600 mg/day)
Number of subjects: 106
Study 11434192 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 846
Study 11434192 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 846
Study 11434192 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 846
Study 11434192 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 846
Study 11434192 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (both doses)
Number of subjects: 846
Study 11434192 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (both doses)
Number of subjects: 846
Study 10024195 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian Gulf-deployed veterans (n = 291)
Number of subjects: 341
Study 10024195 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exposures to pesticides, debris from Scuds, chemical and biological warfare agents, and smoke from tent heaters
Number of subjects: 341
Study 10024195 — intervention group
Group type: COMPARATOR
Intervention: Germany veterans (n = 50)
Number of subjects: 341
Study 8311291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 123
Study 8311291 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 123
Study 8311291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ranitidine 50 mg and metoclopramide 10 mg
Number of subjects: 123
Study 8311291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 3049846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 80 mg/day
Number of subjects: 423
Study 3049846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 30347089 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin only
Number of subjects: 41537
Study 30347089 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant only
Number of subjects: 41537
Study 30347089 — intervention group
Group type: COMPARATOR
Intervention: Both aspirin and anticoagulant
Number of subjects: 41537
Study 30347089 — intervention group
Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 41537
Study 26849409 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-coach and nurse-partnered interventions
Number of subjects: 600
Study 26849409 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse program contract within a residential drug treatment program
Number of subjects: 600
Study 26849409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spent 90 days or greater in a residential drug treatment program
Number of subjects: 600
Study 25146492 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1 g/day)
Number of subjects: 200
Study 25146492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same fruit drink without omega-3)
Number of subjects: 200
Study 24189232 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance refinement functionality in Phaser
Number of subjects: 21000
Study 24189232 — intervention group
Group type: EXPERIMENTAL
Intervention: New estimate of the r.m.s.d. using sequence identity and protein size
Number of subjects: 21000
Study 24189232 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbing the initial estimate of the r.m.s.d.
Number of subjects: 21000
Study 21189110 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip arthroplasty (n = 41)
Number of subjects: 85
Study 21189110 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene hip arthroplasty (n = 44)
Number of subjects: 85
Study 19151303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group received 500 mL of saline plus 500 mL of 6% HES 130/0.4
Number of subjects: 60
Study 19151303 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline group received 500 mL saline
Number of subjects: 60
Study 19151303 — intervention group
Group type: COMPARATOR
Intervention: Control group received no intravascular volume preload
Number of subjects: 60
Study 16864812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) defined by a glomerular filtration rate < or =60 mL/minute/1.73 m2
Number of subjects: 6685
Study 16864812 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of 1 SD in GFR
Number of subjects: 6685
Study 15669380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen treatment at 0.01 mg active ingredient/liter
Number of subjects: 12
Study 15669380 — intervention group
Group type: COMPARATOR
Intervention: Control group (residual house spraying with lambdacyhalothrin)
Number of subjects: 12
Study 10958143 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 19
Study 10958143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9129861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines for the common cold
Number of subjects: 0
Study 9129861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8456759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day, increased to 40 and 80 mg/day at weeks 6 and 12
Number of subjects: 672
Study 8456759 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day, increased to 20 and 40 mg/day at weeks 6 and 12
Number of subjects: 672
Study 3533672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 31
Study 3533672 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 31
Study 3533672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29275856 — intervention group
Group type: EXPERIMENTAL
Intervention: 64mg/day MIN-101
Number of subjects: 244
Study 29275856 — intervention group
Group type: EXPERIMENTAL
Intervention: 32mg/day MIN-101
Number of subjects: 244
Study 29275856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 27486051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive patient education intervention
Number of subjects: 203
Study 27486051 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 25590188 — intervention group
Group type: EXPERIMENTAL
Intervention: Wing-shaped plastic stent
Number of subjects: 37
Study 25590188 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 37
Study 23886644 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 1.2g daily for 24 weeks
Number of subjects: 14
Study 23886644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23886644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment and placebo arms combined
Number of subjects: 14
Study 20521985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized whey supplementation
Number of subjects: 22
Study 20521985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein)
Number of subjects: 22
Study 19032398 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) tubes
Number of subjects: 33
Study 19032398 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tubes (NGT)
Number of subjects: 33
Study 19032398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PEG and NGT
Number of subjects: 33
Study 19032398 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG tubes
Number of subjects: 33
Study 16453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 551
Study 16453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-Plug technique
Number of subjects: 551
Study 16453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS) technique
Number of subjects: 551
Study 16453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 551
Study 12717484 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg tid)
Number of subjects: 166
Study 12717484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 10764316 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor zileuton
Number of subjects: 18
Study 10764316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10764316 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 18
Study 9034259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human albumin (25 g/day)
Number of subjects: 36
Study 9034259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9034259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human albumin
Number of subjects: 36
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirated oedema fluid
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Wick fluid from oedematous arm
Number of subjects: 39
Study 8287667 — intervention group
Group type: COMPARATOR
Intervention: Wick fluid from non-swollen arm
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirate protein concentration to serum protein concentration ratio
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum protein concentration in oedema patients
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin concentration in oedema patients
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oedema patients receiving tamoxifen
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan concentration in oedema fluid
Number of subjects: 39
Study 8287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscosity of oedema fluid
Number of subjects: 39
Study 2881799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 18
Study 2881799 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 18
Study 31425752 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 supplements (3000 mg)
Number of subjects: 43
Study 31425752 — intervention group
Group type: COMPARATOR
Intervention: placebo (refined olive oil)
Number of subjects: 43
Study 30178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (Group A, n = 30)
Number of subjects: 60
Study 30178092 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin (Group B, n = 30)
Number of subjects: 60
Study 30178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline/Terlipressin
Number of subjects: 60
Study 28143522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/day)
Number of subjects: 180
Study 28143522 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose aspirin (325 mg/day)
Number of subjects: 180
Study 28143522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 24417614 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 46
Study 24417614 — intervention group
Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 46
Study 24417614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both titanium and zirconia abutments
Number of subjects: 46
Study 24417614 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 46
Study 23070723 — intervention group
Group type: EXPERIMENTAL
Intervention: New RSA method for wear measurements without previous radiographs
Number of subjects: 27
Study 23070723 — intervention group
Group type: COMPARATOR
Intervention: Conventional RSA method for wear measurements
Number of subjects: 27
Study 20650376 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbicularis oris group (n=18)
Number of subjects: 36
Study 20650376 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 36
Study 18258794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 M hydrochloric acid (HCl) infusion
Number of subjects: 20
Study 18258794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 M hydrochloric acid (HCl) infusion
Number of subjects: 20
Study 18258794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 M hydrochloric acid (HCl) infusion
Number of subjects: 20
Study 18258794 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 16633299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/infusional 5-FU combination (OXFU)
Number of subjects: 32